Amarin Corp Plc (AMRN)

[BioChica]

J.L.

From page 87:

Reducing Residual Cardiovascular Risk.—Cardiovascular events account for one of every three deaths in the United States; about
2,300 Americans die of cardiovascular disease each day. Cholesterol therapies, such as statins, have been successful in reducing risk of cardiovascular disease, but substantial residual and untreated risk remains for these individuals beyond cholesterol management.

A clinical trial called REDUCE-IT has demonstrated a 25 percent relative risk reduction in major adverse cardiovascular events beyond cholesterol management, from the use of highly purified and stable eicosapentaenoic acid (EPA) in addition to statin therapy.

The Committee is concerned that, despite these statistics, many individuals do not regularly access treatments for residual risk beyond statin therapy. The Committee urges NHLBI to support research in this area as well as efforts, particularly through the ‘‘Know Your Numbers’’ campaign, to promote awareness among physicians and patients of the residual cardiovascular risks beyond statin therapy and the importance of taking preventative action to reduce this risk.